Idogen has announced that the Japan Patent Office (“JPO”) has granted the company’s patent application. The patent provides Idogen’s vaccine technology with a broad protection and further strengthens the company’s patent portfolio in an important market.

The Japan Patent Office has now formally granted Idogen’s Patent Application covering induction of IDO for treatment of autoimmune diseases and transplant rejection. The patent, granted with patent number 6063392, belongs to Idogen’s second patent family and broadly covers Idogen’s technology in Japan until 2031. Related patent applications in this family are pending in Canada and the US and received a “Notice of Intention to Grant” in Europe in January 2017. Idogen’s first patent family concerns additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs and is so far granted in Europe.

”The granting of our patent application in Japan is pleasing and a statement representing a considerable strengthening of Idogen’s patent portfolio,” said CEO Lars Hedbys.